News & Updates

Show Multimedia Only

Adverse events push RA-ILD patients to discontinue nintedanib

23 May 2025

In patients with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), combination therapy with disease-modifying antirheumatic drugs (DMARDs) does not negatively influence the safety and efficacy of nintedanib, reports a study. The main drivers of drug withdrawal or dose reduction in these individuals are adverse events (AEs), primarily due to comorbidities.

Adverse events push RA-ILD patients to discontinue nintedanib

23 May 2025

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025 by

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025 by

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025

Dupilumab improves disease severity, PROs in children with AD

23 May 2025 by

Treatment with dupilumab improved disease severity and patient-reported outcomes (PROs) in paediatric patients aged <12 years with moderate-to-severe atopic dermatitis (AD), according to a 4-year interim analysis of the PEDISTAD* trial presented at PAS 2025.

Dupilumab improves disease severity, PROs in children with AD

23 May 2025

Pegcetacoplan works for teens with rare kidney diseases

22 May 2025 by

Off-label use of the central C3/C3b inhibitor pegcetacoplan is well tolerated and delivers improved outcomes for adolescents with C3 glomerulopathy (C3G) and immune complex-membranoproliferative glomerulonephritis (IC-MPGN), according to a subgroup analysis of the phase III VALIANT trial.

Pegcetacoplan works for teens with rare kidney diseases

22 May 2025

Seladelpar benefit in PBC sustained at 3 years

22 May 2025 by

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.

Seladelpar benefit in PBC sustained at 3 years

22 May 2025

Apixaban a safe oral anticoagulant choice for VTE patients

22 May 2025

For patients with venous thromboembolism (VTE) who are initiating an oral anticoagulant, apixaban use appears to be safer than rivaroxaban and warfarin, with lower risks of VTE recurrence and major bleeding, as reported in a study.

Apixaban a safe oral anticoagulant choice for VTE patients

22 May 2025

Hypoglycaemia often occurs in insulin-treated hyperkalemia patients

21 May 2025 by

The use of intravenous (IV) insulin for managing hyperkalemia in hospitalized patients may lead to hypoglycaemia, which occurs more frequently in those with kidney-related conditions, according to a Singapore study.

Hypoglycaemia often occurs in insulin-treated hyperkalemia patients

21 May 2025

Rizatriptan not supported for treating vestibular migraine

20 May 2025

Rizatriptan does not appear to be efficacious in the treatment of vestibular migraine attacks, showing no clear beneficial effects on any symptoms and on vertigo in a randomized clinical trial.

Rizatriptan not supported for treating vestibular migraine

20 May 2025

Darbepoetin improves erythropoietic response but not cognitive outcomes in preterm infants

19 May 2025

Administering darbepoetin infusions to preterm infants does not appear to help with cognitive outcomes, although it increases hematocrit values and reduces blood transfusions and donor exposures, according to a study.

Darbepoetin improves erythropoietic response but not cognitive outcomes in preterm infants

19 May 2025

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Adverse events push RA-ILD patients to discontinue nintedanib

Adverse events push RA-ILD patients to discontinue nintedanib

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

GLP-1RAs help reduce risk of gastrointestinal cancers

GLP-1RAs help reduce risk of gastrointestinal cancers

Dupilumab improves disease severity, PROs in children with AD

Dupilumab improves disease severity, PROs in children with AD

Pegcetacoplan works for teens with rare kidney diseases

Pegcetacoplan works for teens with rare kidney diseases

Seladelpar benefit in PBC sustained at 3 years

Seladelpar benefit in PBC sustained at 3 years

Apixaban a safe oral anticoagulant choice for VTE patients

Apixaban a safe oral anticoagulant choice for VTE patients

Hypoglycaemia often occurs in insulin-treated hyperkalemia patients

Hypoglycaemia often occurs in insulin-treated hyperkalemia patients

Rizatriptan not supported for treating vestibular migraine

Rizatriptan not supported for treating vestibular migraine

Darbepoetin improves erythropoietic response but not cognitive outcomes in preterm infants

Darbepoetin improves erythropoietic response but not cognitive outcomes in preterm infants